Cambridge Cognition WP

News

BMS’ schizophrenia treatment reduces symptoms in Phase III trial

KarXT had a favourable impact on weight and metabolic parameters in the trial.

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

BMS’ schizophrenia treatment reduces symptoms in Phase III trial

Healthcare IT consulting firms, services and companies

Clinical trial technology, companies and solutions

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

Sign up for our daily news round-up!

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Thank you for subscribing